Karyopharm Therapeutics Inc (KPTI)

9.46
0.27 2.80
NASDAQ : Health Care
Prev Close 9.73
Open 9.68
Day Low/High 9.43 / 9.80
52 Wk Low/High 4.83 / 23.59
Volume 189.20K
Avg Volume 392.30K
Exchange NASDAQ
Shares Outstanding 35.99M
Market Cap 348.74M
EPS -3.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug

Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug

Karyopharm announced study results in which its experimental drug selinexor demonstrated a 20% tumor response rate in multiple myeloma patients no longer responsive to four or five currently approved therapies.

Markets Very Sluggish as August Nears an End

Markets Very Sluggish as August Nears an End

Even concerns about a possible Fed rate hike do not appear to be affecting traders.

Noteworthy Monday Option Activity: KPTI, SHLD, MXWL

Noteworthy Monday Option Activity: KPTI, SHLD, MXWL

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Karyopharm Therapeutics Inc , where a total volume of 2,316 contracts has been traded thus far today, a contract volume which is representative of approximately 231,600 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 168.7% of KPTI's average daily trading volume over the past month, of 137,260 shares.

These 7 Stocks Under $10 Could Make You a Lot of Money

These 7 Stocks Under $10 Could Make You a Lot of Money

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Karyopharm To Report Second Quarter 2016 Financial Results On August 4, 2016

Karyopharm To Report Second Quarter 2016 Financial Results On August 4, 2016

Conference Call Scheduled for Thursday, August 4, 2016 at 8:30 a.m. ET

Commit To Purchase Karyopharm Therapeutics At $5, Earn 20.6% Annualized Using Options

Commit To Purchase Karyopharm Therapeutics At $5, Earn 20.6% Annualized Using Options

Investors considering a purchase of Karyopharm Therapeutics Inc stock, but tentative about paying the going market price of $7.38/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2017 put at the $5 strike, which has a bid at the time of this writing of 60 cents.

Karyopharm Initiates Phase 1 Clinical Trial With KPT-9274

Karyopharm Initiates Phase 1 Clinical Trial With KPT-9274

First-in-class Immunometabolic Modulator, PAK4/NAMPT Inhibitor, to be Evaluated in Patients with Advanced Solid Malignancies or Non-Hodgkin's Lymphoma

Oversold Conditions For Karyopharm Therapeutics (KPTI)

Oversold Conditions For Karyopharm Therapeutics (KPTI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Insider Trading Alert - TRUP, KPTI And FCBC Traded By Insiders

Insider Trading Alert - TRUP, KPTI And FCBC Traded By Insiders

Stocks with insider trader activity include TRUP, KPTI and FCBC

Insider Trading Alert - KPTI, CPIX And LB Traded By Insiders

Insider Trading Alert - KPTI, CPIX And LB Traded By Insiders

Stocks with insider trader activity include KPTI, CPIX and LB

Insider Trading Alert - W, KPTI And GVP Traded By Insiders

Insider Trading Alert - W, KPTI And GVP Traded By Insiders

Stocks with insider trader activity include W, KPTI and GVP

Karyopharm To Present Preliminary STOMP Phase 1B Clinical Data At 2016 European Hematology Association Annual Meeting

Karyopharm To Present Preliminary STOMP Phase 1B Clinical Data At 2016 European Hematology Association Annual Meeting

- Data Describes Early Activity of Selinexor in Combination with Standard of Care Agents for Treatment of Relapsed/Refractory Multiple Myeloma -

Karyopharm To Present Selinexor Clinical Data At The American Society Of Clinical Oncology Annual Meeting

Karyopharm To Present Selinexor Clinical Data At The American Society Of Clinical Oncology Annual Meeting

Single-agent Selinexor in Recurrent Glioblastoma and Selinexor Combination Data in Multiple Myeloma

Karyopharm To Report First Quarter 2016 Financial Results On May 9, 2016

Karyopharm To Report First Quarter 2016 Financial Results On May 9, 2016

Conference Call Scheduled for Monday, May 9, 2016 at 8:30 a.m. ET

Karyopharm Presents Data Demonstrating The Potential Of Nuclear Export Protein Exportin 1 (XPO1) Inhibition In The Treatment Of Traumatic Brain Injury

Karyopharm Presents Data Demonstrating The Potential Of Nuclear Export Protein Exportin 1 (XPO1) Inhibition In The Treatment Of Traumatic Brain Injury

Preclinical data on KPT-350, Karyopharm's Selective Inhibitor of Nuclear Export (SINEā„¢) compound, presented at the 2016 American Academy of Neurology Annual Meeting